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Key questions 
 
What is already known about this subject?  
Mortality after PCI to the unprotected left main stem (UPLMS) is higher among emergency 
and urgent cases than elective cases and it is especially high among patients with 
cardiogenic shock. Following PCI, however, the dominant cause of death is non-
cardiovascular. 
 
What does this study add?  
After adjusting for background population mortality, we found that long-term survival following 
UPLMS PCI for elective cases was excellent, approached that of the background populace and 
was significantly predicted by co-morbidity. For NSTEACS and STEMI without cardiogenic 
shock, the requirement for pre-procedural ventilation was the strongest determinant of excess 
mortality.  For STEMI with cardiogenic shock, where survival was poor, the strongest 
determinant was TIMI flow.  
 
How might this impact on clinical practice? 
Greater attention to specific determinants of excess mortality, such as diabetes, renal failure 
and coronary anatomy, according to whether a case is emergent, urgent or elective will help 
improve survival following UPLMS PCI. Knowledge of clinical presentation-specific factors 
associated with excess mortality will allow better forecasting of outcomes for patients with 
UPLMS disease. The poor and persistently low survival among STEMI with cardiogenic 
shock requires greater clinical attention.  
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Abstract 
Objective 
For percutaneous coronary intervention (PCI) to the unprotected left main stem (UPLMS), 
there are limited long-term outcome data. We evaluated five year survival for UPLMS PCI 
cases taking into account background population mortality.  
 
Methods  
A population-based registry of 10,682 cases of chronic stable angina (CSA), non ST-
segment elevation acute coronary syndrome (NSTEACS), ST-segment elevation myocardial 
infarction with (STEMI+CS) and without cardiogenic shock (STEMI-CS) who received 
UPLMS PCI from 2005 to 2014 were matched by age, sex, year of procedure and country to 
death data for the United Kingdom populace of 56.6 million people. Relative survival and 
excess mortality were estimated.  
 
Results 
Over 26,105 person-years follow-up, crude five year relative survival was 93.8% for CSA, 
73.1% NSTEACS, 77.5% STEMI-CS and 28.5% STEMI+CS. The strongest predictor of 
excess mortality among CSA was renal failure (EMRR 6.73, 95% CI 4.06-11.15), and for 
NSTEACS and STEMI-CS was pre-procedural ventilation (6.25, 5.05-7.75 and 6.92, 4.25-
11.26, respectively). For STEMI+CS, the strongest predictor of excess mortality was pre-
procedural TIMI 0 flow (2.78, 1.87-4.13), whereas multivessel PCI was associated with 
improved survival (0.74, 0.61-0.90).   
 
Conclusions 
Long term survival following UPLMS PCI for CSA was high, approached that of the 
background populace and was significantly predicted by co-morbidity. For NSTEACS and 
STEMI-CS, the requirement for pre-procedural ventilation was the strongest determinant of 
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excess mortality. By contrast, among STEMI+CS, in whom survival was poor, the strongest 
determinant was pre-procedural TIMI flow. Future cardiovascular cohort studies of long-term 
mortality should consider the impact of non-cardiovascular deaths. 
 
Keywords 
Unprotected left main stem; percutaneous coronary intervention; relative survival; excess 
mortality; STEMI; NSTEACS; chronic stable angina; cardiogenic shock 
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Introduction  
 
Improved stent technology, the de novo presentation of unprotected left main stem (UPLMS) 
coronary disease at primary percutaneous coronary intervention (PPCI) and evidence from 
randomised trials reporting good outcomes among higher risk patients has increased the 
number of patients who receive PCI to the UPLMS [1-3]. Among emergent, urgent and 
elective cases of UPLMS PCI, procedural success is high with evidence of over 95% 
technical success and excellent short-term outcomes [4]. 
 
However, there is a paucity of representative data regarding the longer-term outcomes 
following UPLMS PCI. In part, this is due to the inherent bias of small observational cohorts 
and difficulty in generalising results from the highly selected cohorts recruited into 
randomised trials, but also because long-term survival studies of UPLMS PCI typically report 
all-cause mortality [5, 6]. The latter point is of particular importance when, nowadays, the 
dominant cause of death after PCI is non-cardiovascular and if not accounted for, the 
efficacy of UPLMS PCI may be underestimated.  
 
Whilst cause-specific mortality records can help ascertain the effect of an intervention on 
cardiovascular outcomes, this approach has its limitations. Cause-specific mortality records 
may be difficult to ascertain and when available are limited to trials or if obtained from 
administrative data can be biased by misclassification of the cause of death [7]. An 
alternative method to estimate cause-specific outcomes is relative survival, which adjusts for 
the expected rates of death in the general population. Using a relative survival approach and 
all cases of UPLMS PCI within the United Kingdom health care system, we aimed to report 
the rates of relative survival and then quantify the determinants of excess mortality among 
emergent, urgent and elective cases of UPLMS PCI. To achieve this, we matched cases of 
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UPLMS PCI from the British Cardiovascular Intervention Society (BCIS) national registry of 
PCI to lifetable data according to age, sex, year of procedure and country for the United 
Kingdom general populace of 56.6 million people. This allowed mortality and factors 
specifically associated with UPLMS disease and its treatment to be studied [8].  
 
Methods 
Patients, setting and inclusion criteria 
 
Participation in BCIS is mandated for all operators and all National Health Service Providers 
in the United Kingdom. The sampling frame consisted of all cases from the 1st January 2005 
to 1st July 2014 [9]. Data for every PCI performed, comprising 113 core fields [9] were 
collected prospectively, encrypted and transferred online to a central database at the 
National Institute for Cardiovascular Outcomes Research (NICOR). Patients included had 
PCI to a diseased UPLMS and were aged 18 to 100 years. Cases of UPLMS PCI were those 
in whom the left main stem was the target vessel and who did not have a patent graft to any 
left sided coronary artery (Figure 1) [9]. For those with multiple records, the first admission 
was used. According to the joint ESC/ACC consensus statement guidelines for definition for 
myocardial infarction, we grouped cases as chronic stable angina (CSA), non ST-elevation 
acute coronary syndrome (NSTEACS) and ST-elevation myocardial infarction (STEMI) [10]. 
To minimise bias due to the inclusion of patients with cardiogenic shock in the STEMI group, 
we subdivided STEMI cases into those with (STEMI+CS) and without cardiogenic shock 
(STEMI-CS); both groups only included patients who received primary PCI. The diagnosis of 
cardiogenic shock was clinical and included a systolic blood pressure <100 mmHg, 
pulse >100 bpm, in a patient who was cool and clammy or requiring inotropes, intra-aortic 
balloon pump or other cardiopulmonary support.  
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Mortality and follow up 
 
All-cause mortality data for UPLMS PCI cases were extracted through linkage to the Office 
for National Statistics using each patient’s unique pseudonymised National Health Service 
number. Patients were followed-up for their vital status up to 5 years after PCI, with 
censoring at the end of follow-up on 1st July, 2014 (Figure 1a, Appendix). Survival time was 
defined as the duration between the date of the procedure and the date of death or 
censoring.  
 
Relative survival  
 
Relative survival was defined as the observed survival among cases of UPLMS PCI divided 
by the expected survival of the comparable United Kingdom populace and expressed as 
relative survival rates (RSR) [11]. A relative survival rate of 100% implies that cases of 
UPLMS PCI have survival rates equal to that of the matched disease free background 
population. Observed survival was estimated using the actuarial method which calculates 
the observed survival in time intervals from the effective number of patients at risk in that 
particular interval and the expected survival by the Ederer II method [11]. For expected 
survival, country-specific population mortality rates of the United Kingdom were based on life 
tables from the Office for National Statistics matched to the cohort by single year of age, sex 
and year of procedure.  
 
Excess mortality  
 
Excess mortality provides a measure of the additional hazard associated with a procedure or 
treatment and is expressed as a rate ratio (EMRR). Evidence of excess mortality is observed 
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when the EMRR is greater than 1. For example, an EMRR of 1.5 for men/women indicates 
that men experience 50% higher excess mortality than women. The statistical model 
comprised generalised linear regression models, collapsed (life table) data, and a Poisson 
error structure [11]. First, we fitted a baseline model comprising age, sex and year of 
procedure. Each of the following covariates were then separately fitted into the baseline 
moactudel: previous myocardial infarction, previous PCI, diabetes mellitus, left ventricular  
systolic function, number of vessels attempted, number of stents, renal failure (defined as 
serum creatinine >200 µmol/L), cardiogenic shock pre- and post-procedure, degree of LMS 
stenosis pre and post procedure (the presence of stenosis was assigned if a vessel scored 
>50% on the effective stenosis), TIMI flow in the infarct related artery pre- and post-
procedure, pre-procedural  ventilation, use of GPIIb/IIIa inhibitors, use of intravascular 
ultrasound (IVUS) and fractional flow reserve (FFR). The proportional hazards assumption 
was tested by including interaction terms between the three baseline variables (age, sex, 
calendar year) and follow-up time, and using the likelihood ratio test; there were no time 
dependent effects (p>0.05) therefore no interaction terms were added. To mitigate bias due 
to missing data, we generated 20 multiply imputed datasets by chained equations [12]. All 
tests were two-tailed, the level of statistical significance pre-specified at 5% (p<0.05) and 
estimates derived with 95% confidence intervals (CI), statistical analyses were performed 
using Stata version 13.1 (StataCorp). 
 
Ethics 
Ethical approval was not required under NHS research governance arrangements. NICOR 
which includes the BCIS database (Ref: NIGB: ECC 1-06 (d)/2011) has support under 
section 251 of the National Health Service (NHS) Act 2006 to use patient information for 
medical research without consent.  
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Results 
 
Among 10,682 cases of UPLMS PCI across 89 providers there were 3,799 (35.5%) CSA, 
5,114 (47.8%) NSTEACS, 1,020 STEMI-CS and 749 STEMI+CS of whom 69.1% were male. 
Mean respective ages (SD) were 69.3 (11.2), 72.4 (12.1%), 68.0 (13.7) and 68.2 (12.7) 
years (Table 1). Over 26,105 person-years and median follow-up of 2 years, 2,872 (25.9%) 
died. The crude five year relative survival was 93.8% for CSA, 73.1% for NSTEACS, 77.5% 
for STEMI-CS and 28.5% for STEMI+CS (Figure 2). The number of cases in England, North 
of Ireland, Scotland and Wales were 9,736 (87.1%), 566 (5.2%), 439 (4.1%) and 387 (3.6%), 
respectively.  
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Table 1: Baseline characteristics for cases of UPLMS PCI by CSA, NSTEACS, STEMI-CS 
and STEMI+CS 
 
CSA  
n=3799 
NSTEACS  
n=5114 
STEMI-CS  
n=1020 
STEMI+CS 
n=749 
Missing (%)¥ 
Demographics    
Mean (SD) age, years  69.3 (11.2) 72.4 (12.1) 68.0 (13.7) 68.2 (12.7) 135 (0.1) 
Age greater than 80 years (%) 696/3799 (18.3) 1566/5111 (30.6) 231/1018 (22.7) 131/749 (17.5) 
Male (%) 2788/3765 (74.1) 3307/5091 (65.0) 732/1018 (71.9) 547/746 (73.0) 63 (0.6) 
Medical History   
Previous MI (%) 1105/3446 (32.1) 1863/4630 (40.2) 161/956 (16.8) 125/673 (18.6) 982 (9.2) 
Previous PCI (%) 1183/3779 (31.3) 971/5048 (19.2) 99/1006 (9.8) 80/733 (10.9) 120 (1.1) 
Recent thrombolysis (%) - 163/4447 (3.7) 19/956 (2.0) 10/729 (1.4) 757 (11.0) 
Family history of CAD (%) 1611/3250 (49.6) 1783/4228 (42.2) 265/846 (31.3) 185/557 (33.2) 1811/16.9) 
Diabetes mellitus (%) 755/3651 (20.7) 1184/4905 (24.1) 159/973 (16.3) 132/690 (19.1) 471 (4.4) 
History of renal disease (%) 148/3757 (3.9) 464/5072 (9.2) 31/1017 (3.1) 29/745 (3.9) 93 (0.9) 
Left ventricular systolic function (LVSD)    
Normal (EF ≥50%) (%) 1960/2667 (73.5) 1616/3527 (45.8) 125/380 (32.9) 43/350 (12.3) 3767 (35.2) 
Moderate LVSD (EF 30-49%) (%) 466/2667 (17.5) 1183/3527 (33.5) 167/380 (44.0) 98/350 (28.0) 
Severe LVSD (EF<30%) (%) 241/2667 (9.0) 728/3527 (20.6) 88/380 (23.2) 209/350 (59.7) 
Angiographic findings   
LMS Stenosis 
<50% 987/3500 (28.2) 962/4714 (20.4) 246/966 (25.5) 75/701 (10.7) 806  (7.5) 
≥ 50% 2513/3500 (71.8) 3752/4714 (79.6) 720/966 (74.5) 626/701 (89.3) 
Flow in IRA 
TIMI 0 (%) 58/1197 (4.9) 101/1450 (7.0) 454/881 (51.5) 391/661 (59.2) 6501 (60.8) 
TIMI 1 (%) 30/1197 (2.5) 113/1450 (8.0) 82/881 (9.3) 91/661 (13.8) 
TIMI 2 (%) 81/1197 (6.8) 209/1450 (14.4) 153/881 (17.4) 99/661 (15.0) 
TIMI 3 (%) 1028/1197 (85.9)   1027/1450 (70.8) 192/881 (21.8) 80/661 (12.1) 
Procedure   
Requirement for mechanical ventilation 17/3270 (0.5) 217/4648 (4.7) 51/931 (5.5) 251/699 (35.9) 1145 (10.7) 
Arterial 
access 
Femoral (%) 2014/3722 (54.1) 2608/5038 (51.8) 420/1001 (42.0) 519/729 (71.2) 192 (1.8) 
Radial (%) 1693/3722 (45.4) 2398/5038 (47.6) 579/1001 (57.8) 208/729 (28.5) 
Others (%) 15/3722 (0.4) 32/5038 (0.6) 2/1001 (0.2) 2/729 (0.3) 
Vessels 
attempted  
LMS only (%) 1047/3799 (27.6) 1440/5114 (28.2) 282/1020 (27.7) 238/749 (31.8) 0 
LMS and another vessel (%) 2752/3799 (72.4) 3674/5114 (71.8) 738/1020 (72.4) 511/749 (68.2) 
Total number 
stents used 
0 (%) 322/3786 (8.5) 267/5091 (5.2) 54/1018 (5.3) 68/743 (9.2) 46 (0.4) 
1 (%) 1118/3786 (29.5) 1617/5091 (31.8) 304/1018 (29.9) 259/743 (34.9) 
>1(%)  2346/3786 (62.0) 3207/5091 (63.0) 660/1018 (64.8) 416/743 (56.0) 
Glycoprotein IIb/IIIa  inhibitor  696/3565 (19.5) 1396/4855 (28.8) 559/969 (57.7) 453/729 (62.1) 566 (5.3) 
Diagnostic device (IVUS) 1671/3611 (46.3) 1725/4860 (35.5) 225/968 (23.2) 64/728 (8.8) 515 (4.8) 
Diagnostic device (FFR) 474/3611 (13.1) 237/4860 (4.9) 10/958 (1.0) 4/724 (0.6) 515 (4.8) 
Procedural success   
LMS stenosis 
<50% 3264/3451 (94.6) 4440/4629 (95.9) 909/958 (94.9) 629/695 (90.5) 953 (8.9) 
≥50% 187/3451 (5.4) 189/4627 (4.1) 49/958 (5.1) 66/695 (9.5) 
Flow in IRA 
TIMI 0 (%) 26/1420 (1.8) 48/2729 (1.8) 56/899 (6.2) 63/677 (9.3) 4963 (46.4) 
TIMI 1 (%) 5/1420 (0.4) 9/2729 (0.3) 12/899 (1.3) 40/677 (5.9) 
TIMI 2 (%) 19/1420 (1.3) 43/2729 (1.6) 44/899 (4.9) 107/677 (15.8) 
TIMI 3 (%) 1370/1420 (96.5) 2629/2729 (96.3) 787/899 (87.5) 467/677 (69.0) 
Abbreviation: ¥, missing of the total=10,697; MI, acute myocardial infarction; PCI, percutaneous coronary 
intervention; CAD, cardiovascular disease; LVSD, Left ventricular systolic function; EF, ejection fraction; FFR, 
fractional flow reserve; LMS, Left main stem; IRA, infarct-related artery; TIMI, thrombolysis in myocardial 
infarction; IVUS, intravascular ultrasound; -, not eligible  
 
 
Five year relative survival by age, sex and year 
 
Five year relative survival was worse among the elderly (Figure 3). For cases of CSA aged 
<55 and > 75 years it was 96.3% vs. 96.2% and for NSTEACS 84.1% vs. 71.2%, STEMI-CS 
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90.1% vs.74.8% and STEMI+CS 41.2% vs.25.0% (Figure 3).  For females and males, 
survival was 96.2% vs. 92.8% for CSA, 70.2% vs. 74.5% for NSTEACS; 60.0% vs. 55.8% for 
STEMI-CS and 36.4% vs. 25.8% for STEMI+CS (Figure 4). Between 2005/6 and 2009/10, 
survival rates improved; increasing for CSA (90.8% to 95.5%), NSTEACS (76.5% to 72.5%), 
STEMI-CS (72.2% to 76.4%) and with the greatest improvements among STEMI+CS (23.9% 
to 32.4%) (Figure 5).  
 
Excess mortality by age, sex and year 
 
For CSA, there was no evidence of excess mortality by age, sex or year of diagnosis. There 
was, however, significant excess mortality with increasing age (>75 compared with <55 
years) for NSTEACS (EMRR 2.61, 95% CI 1.91-3.57) and STEMI-CS (3.49, 1.99-6.10), but 
not by sex and year of procedure. Among STEMI+CS excess mortality occurred with 
increasing age (1.73, 1.29-2.33), but not sex and there was a significant reduction in excess 
mortality for 20011/12 (0.54, 0.33-0.91) and 2013/14 (0.55, 0.33-0.91) compared with 2005/6 
(Table 3a, Appendix).  
 
Determinants of excess mortality 
 
For CSA, excess mortality was associated with previous myocardial infarction (2.73, 1.77- 
4.21), diabetes (2.56, 1.64-3.97), moderate (2.43, 1.38-4.29) and poor left ventricular systolic 
function (3.90, 2.23 - 6.82), renal failure (6.73, 4.06-11.15) and pre-procedural stenosis 
severity (EMRR 1.82, 95% CI 1.02-3.23) (Table 2). There was a significant reduction of 
excess mortality associated with the use of IVUS (EMRR 0.46, 95% CI 0.28-0.76). Others 
variables such as the number of vessels attempted, the number of stents deployed and the use 
of a GPIIb/IIIa were not significantly associated with excess mortality.  
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For NSTEACS, excess mortality was associated with previous myocardial infarction (EMRR 
1.55, 95% CI 1.34-1.80), diabetes (1.66, 1.43-1.95), moderate (2.34, 1.86-2.93) and poor left 
ventricular systolic function (3.65, 2.96-4.51), renal failure (3.25, 2.75-3.84), pre-procedural 
ventilation (6.25, 5.05-7.75) and pre-procedural LMS disease severity (2.09, 1.64-2.66). 
Reduced excess mortality was significantly associated with IVUS (EMRR 0.47, 95% CI 0.39-
0.57) and FFR (0.44, 0.25-0.75).  
 
Among cases of STEMI-CS, excess mortality was associated with diabetes (EMRR 1.69, 95% 
CI 1.15 - 2.48), renal failure (2.27, 1.20- 4.27), TIMI 1 flow versus normal flow (1.99, 1.01 - 3.92), 
pre-procedural ventilation (6.92, 4.25-11.26) and the LMS disease severity (1.60, 1.01- 2.41). 
Factors which were associated with reduced excess mortality were the deployment of one (0.31, 
0.18-0.54) or more stents (0.32, 0.20-0.53), the use of GPIIb/IIIa inhibitors (0.42, 0.29-0.59) and 
the use of IVUS (0.43, 0.24-0.74).  
 
For STEMI+CS, excess mortality was associated with diabetes (EMRR 1.34, 95% CI1.04 - 
1.72), renal failure (1.77, 1.13-2.75), pre-procedural ventilation (2.03, 1.66-2.50) and any degree 
of reduction of pre-procedural TIMI flow versus the normal flow (TIMI 0: EMRR 2.78, TIMI 1: 
2.32, TIMI 2: 2.00). Factors significantly associated with reduced excess mortality were 
multivessel PCI (EMRR 0.74, 95% CI 0.61-0.90), deployment of stents versus no stent (one 
stent: 0.45, 0.32-0.62), more than one stent (0.42, 0.31-0.57) and IVUS (0.28, 0.17-0.46). 
Neither pre-procedural degree of LMS stenosis or GPIIb/IIIa inhibitors were associated with 
excess mortality.  
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Table 2: Factors associated with excess mortality for cases of UPLMS PCI by CSA, 
NSTEACS, STEMI-CS and STEMI+CS. Results are pooled estimates over 20 imputations.  
Abbreviation: *, significance at 5% level; Ŧ, level of missingness detected >50% hence variable not imputed and 
excluded from model; MI, acute myocardial infarction; cardiovascular disease; LVSD, Left ventricular systolic 
function; IRA, infarct-related artery; TIMI, thrombolysis in myocardial infarction; PCI, percutaneous coronary; 
LMS, Left main stem; IVUS, intravascular ultrasound; ^, small number of cases; FFR, fractional flow reserve.   
 
Variable added to baseline 
CSA 
(n=3799) 
NSTEACS 
(n=5114) 
STEMI-CS 
(n=1020) 
STEMI+CS  
(n=749) 
EMRR EMRR EMRR EMRR 
Baseline model + Previous MI 2.73 (1.77- 4.21)* 1.55 (1.34 - 1.80)* 1.18 (1.79 - 1.77) 0.97 (0.75 - 1.26) 
Baseline model + Diabetes  2.56 (1.64-3.97)* 1.66 (1.43 - 1.95)* 1.69 (1.15 - 2.48)* 1.34 (1.04 - 1.72)* 
Baseline model + LVSD   
Good  1.00 1.00 Ŧ Ŧ 
Moderate LVSD 2.43 (1.38 - 4.29)* 2.34 (1.86 - 2.93)* 
Severe LVSD 3.90 (2.23 - 6.82)* 3.65 (2.96 - 4.51)* 
Baseline model + Renal Failure 6.73 (4.06 - 11.15)* 3.25 (2.75 - 3.84)* 2.27 (1.20 - 4.27)* 1.77 (1.13 - 2.75)* 
Baseline model + Pre-procedure flow in IRA  
TIMI 3 (Normal flow) (reference) 1.00  1.00  1.00 1.00 
TIMI 0 (No flow) ^ ^ 1.66 (0.96-2.87) 2.78 (1.87-4.13)* 
TIMI 1 (Partial flow)   1.99 (1.01-3.92)* 2.32 (1.49 - 3.63)* 
TIMI 2 (Slow flow) 1.40 (0.74-2.65) 2.00 (1.26-3.17)* 
Baseline model + Vessels attempted 
One vessel  1.00  1.00  1.00  1.00  
Multivessel PCI 1.52 (0.85 - 2.71) 0.90 (0.77 - 1.05) 0.88 (0.62 - 1.24) 0.74 (0.61 - 0.90)* 
Baseline model + Number of stents  
No stent   1.00 1.00 1.00 1.00 
One stent  1.25 (0.41 - 3.77) 0.93 (0.67 - 1.29) 0.31 (0.18 - 0.54)* 0.45 (0.32 - 0.62)* 
More than one stent  2.20 (0.79 - 6.12) 0.92 (0.68 - 1.26) 0.32 (0.20 - 0.53)* 0.42 (0.31 - 0.57)* 
Other interventions 
Baseline model + Pre procedural ventilation  ^ 6.25 (5.05 - 7.75)* 6.92 (4.25 - 11.26)* 2.03 (1.66-2.50)* 
Baseline model+LMS stenosis pre-procedure  1.82 (1.02 - 3.23)* 2.09 (1.64 - 2.66)* 1.60 (1.01 - 2.41)* 1.03 (0.73-1.43) 
Baseline model + GPIIb/IIa inhibitors 0.87 (0.51 - 1.49) 0.99 (0.84 - 1.17) 0.42 (0.29 - 0.59)* 0.83 (0.68 - 1.02) 
Baseline model + IVUS  0.46 (0.28 - 0.76)* 0.47 (0.39 - 0.57)* 0.43 (0.24 - 0.74)* 0.28 (0.17 - 0.46)* 
Baseline model +  FFR  0.30 (0.08-1.19) 0.44 (0.25-0.75)* ^ ^ 
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Discussion  
 
This is the first population-based study estimating long-term relative survival for patients who 
received PCI to an UPLMS. Relative survival provides an objective measure of the 
proportion of patients dying from direct or indirect consequences of a disease without 
requiring a record of the precise cause of death [11]. To date, studies of UPLMS PCI have 
focused on observed survival and, therefore, reported outcomes include not only deaths 
related to the procedure, but also ‘natural’ deaths occurring in the cohort under study [2, 13, 
14]. Our study provides new insights through the analysis of nationwide prospective, 
consecutive series registry data accounting for populace mortality data.   
 
Specifically, we found that survival after UPLMS PCI for elective patients with CSA was very 
high (over 90% survived to five years) and approached that of the age, sex year and country 
matched disease-free general population. Whilst the presence of an acute coronary 
syndrome (either NSTEACS or STEMI) was associated with reduced longer-term survival, 
for NSTEACS and STEMI without cardiogenic shock survival was similar (about 75% 
survived to five years). By contrast, emergent cases of STEMI presenting with cardiogenic 
shock had very poor survival, which was evident immediately after PCI and persisted for 
many years (about 30% survived to five years). Data from this study provides real world 
evidence to substantiate the ACC/AHA guidelines which have upgraded PCI for UPLMS in 
specific circumstances from a class III to a class 1 or IIa procedure [15].   
 
However, our study did identify an improvement among cases of STEMI with cardiogenic 
shock, and it is possible that operators and hospital services are more familiar with the 
urgent management of such cases. It is also possible that improved stents, deployment 
techniques (for complex anatomy) as well as more potent pharmacological treatments have, 
in part, facilitated the temporal improvements. Notwithstanding this, the ‘accelerated failure’ 
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and poor long-term survival among STEMI with cardiogenic shock was very clear. It 
appears, therefore, that the greatest gains for improved outcomes are among high risk cases 
of complex PCI. Survival for these cases was, however, constrained by co-morbidity, poor 
pre-procedural TIMI flow in the infarct related artery and the necessity for pre-procedural 
ventilation, but was associated with an improvement of about 50% with multivessel PCI. 
Given that trials testing the efficacy of the intra-aortic balloon pump have failed to reach their 
primary endpoints and that there is insufficient evidence for the use of percutaneous assist 
devices, a greater focus on technologies which support the myocardium (thereby allowing 
optimal infarct and non-infarct related PCI), improved stent design and enhanced operator 
experience is needed [16].  
 
Whereas, for elective cases of UPLMS PCI, attention to co-morbidities (previous MI, 
diabetes and renal failure), optimisation of left ventricular systolic function and careful 
evaluation of pre-procedural stenosis severity (using IVUS or FFR) is likely to be key to 
maintaining the present rates of survival.  Addressing these factors and using them to help 
predict a patients’ clinical outcome will provide the opportunity for clinicians to discuss in 
greater detail the risks and benefits of the intended procedure. However, as survival rates 
are already very high among this group, future absolute gains are likely to be small.  
 
For NSTEACS, factors that negatively impacted on long-term survival were prior myocardial 
infarction, diabetes, LMS stenosis >50%, moderate and poor left ventricular systolic function, 
renal failure, cardiogenic shock and the requirement for mechanical ventilation. As for 
elective cases, the use of IVUS and FFR was associated with a more than 50% reduction in 
excess mortality. Although our study design cannot determine a cause and effect 
relationship, this observation supports guideline recommendations that careful attention to 
the coronary anatomy and stent deployment are central to good outcomes. Even so, it is 
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possible that in our study, more stable, lower risk, patients were more likely to receive IVUS 
and FFR [17, 18].  
 
For all types of clinical presentations except STEMI with cardiogenic shock, we found that 
multivessel PCI was not associated with a survival advantage. For STEMI complicated by 
cardiogenic shock, multivessel PCI was associated with, on average, a lower relative excess 
mortality of 26%. This novel association warrants further large scale evaluation, especially 
when present data have failed to eliminate the clinical uncertainty about the most 
appropriate way to treat patients with multivessel disease. That is, whilst previous studies 
have not confirmed the benefit of more complete revascularisation in the context of 
cardiogenic shock, recent trials (among those without CS) have questioned the conventional 
view of lesion only revascularisation in STEMI [19, 20].  
 
Strengths and limitations  
Even though relative survival and excess mortality are novel concepts for the evaluation of 
cardiovascular outcomes, these techniques are well established in cancer epidemiology. 
Relative survival is an underused tool in cardiovascular outcome reporting [8], which in an 
era of evidence-based practice and an ageing ‘survivorship’ population merits further 
attention. The use of relative survival for this study has allowed higher resolution estimation 
of survival and excess deaths specifically due to UPLMS disease and its percutaneous 
treatment without requiring potentially unreliable ‘cause of death’ data. 
Whilst this study has other strengths, including the size and quality of data, there were 
limitations. A high prevalence of the index disease among the general population will 
overinflate survival estimates [11]. Although cardiovascular disease is prevalent, this is 
unlikely to be the case for UPLMS disease per se – being identified at diagnostic 
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angiography in 4-6% of cases and estimated at 15 cases per 100,000 population/year [21]. 
Selection bias may have been introduced through the identification and consent of patients, 
which may lead to a healthier cohort than expected.  
 
Conclusions  
In the largest long-term outcomes study of UPLMS PCI, and after adjustment for non-
cardiovascular death, survival for patients with CSA was excellent and approached that of 
the general population. This contrasted with emergency cases and, in particular, STEMI with 
cardiogenic shock where, despite temporal improvements, survival was poor. For NSTEACS 
and STEMI without cardiogenic, pre-procedural ventilation was the strongest determinant of 
excess mortality, in contrast to STEMI with cardiogenic shock where survival was poor and the 
strongest determinant was pre-procedural TIMI flow.   
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Figure legends 
 
Figure 1: Consort diagram of cohort derivation  
Figure 2: Unadjusted five-year cumulative relative survival stratified by A: CSA, B: 
NSTEACS, C: STEMI-CS, D: STEMI+CS, by pre-determined time points 
Figure 3: Unadjusted five-year cumulative relative survival stratified by A: CSA, B: 
NSTEACS, C: STEMI-CS, D: STEMI+CS, by age  
Figure 4: Unadjusted five-year cumulative relative survival stratified by A: CSA, B: 
NSTEACS, C: STEMI-CS, D: STEMI+CS, by sex 
Figure 5: Unadjusted five-year cumulative relative survival stratified by A: CSA, B: 
NSTEACS, C: STEMI-CS, D: STEMI+CS, by calendar year  
